Laurion Capital Management’s Lineage Cell Therapeutics LCTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $55.8K | Buy |
+61,458
| New | +$55.8K | ﹤0.01% | 245 |
|
|
2024
Q1 | – | Sell |
-433,748
| Closed | -$473K | – | 386 |
|
|
2023
Q4 | $473K | Sell |
433,748
-702,723
| -62% | -$766K | ﹤0.01% | 189 |
|
|
2023
Q3 | $1.34M | Sell |
1,136,471
-829,776
| -42% | -$979K | 0.01% | 135 |
|
|
2023
Q2 | $2.77M | Sell |
1,966,247
-411,693
| -17% | -$580K | 0.02% | 88 |
|
|
2023
Q1 | $3.57M | Hold |
2,377,940
| – | – | 0.02% | 84 |
|
|
2022
Q4 | $2.78M | Hold |
2,377,940
| – | – | 0.01% | 101 |
|
|
2022
Q3 | $2.69M | Sell |
2,377,940
-44,427
| -2% | -$50.2K | 0.02% | 114 |
|
|
2022
Q2 | $3.83M | Buy |
+2,422,367
| New | +$3.83M | 0.06% | 82 |
|
|
2020
Q3 | – | Sell |
-12,476
| Closed | -$11K | – | 763 |
|
|
2020
Q2 | $11K | Buy |
+12,476
| New | +$11K | ﹤0.01% | 603 |
|
|
2018
Q2 | – | Sell |
-200,458
| Closed | -$472K | – | 1181 |
|
|
2018
Q1 | $472K | Buy |
+200,458
| New | +$472K | ﹤0.01% | 746 |
|